HK Stock Market Move | INSILICO (03696) rose nearly 8% in the afternoon, reaching a cooperation agreement with SK Biopharmaceuticals in the field of AI-driven research and development in neuroimmunology diseases.

INSILICO (03696) quickly surged in the afternoon, with the stock price rising nearly 8% at one point, and as of the time of writing, it had risen by 4.07% to HK$39.9, with a trading volume of HK$2.36 billion. In terms of news, INSILICO announced that it has reached a research and development cooperation agreement with SK Biopharmaceuticals to explore innovative candidate drugs for central nervous system neuroimmune diseases driven by AI. In this collaboration, INSILICO will use its proprietary Pharma.AI platform, which covers target validation, generative chemistry, and molecular optimization, combined with preclinical drug discovery expertise to discover, design, and optimize novel candidate drugs for neuroimmune indications. SK Biopharmaceuticals will leverage its deep research and clinical capabilities in the field of neuroimmune diseases to lead the later stage development and commercialization of all collaboration projects. According to the terms of the agreement, INSILICO will be eligible to receive up to $18 million in upfront payments and near-term milestone payments. The potential total transaction value of this collaboration exceeds $2.5 billion, covering development, regulatory, and commercialization milestone payments, as well as single-digit percentage sales royalties based on net sales post product commercialization.